Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Growth differentiation factor 15 (GDF15) and semaglutide inhibit food intake and body weight through largely distinct, additive mechanisms
Misgana Y. Ghidewon, Hallie S. Wald, Aaron D. McKnight, et al.
Diabetes Obesity and Metabolism (2022) Vol. 24, Iss. 6, pp. 1010-1020
Open Access | Times Cited: 29

Showing 1-25 of 29 citing articles:

The glucagon-like peptide-1 (GLP-1) analogue semaglutide reduces alcohol drinking and modulates central GABA neurotransmission
Vicky Chuong, Mehdi Farokhnia, Sophia Khom, et al.
JCI Insight (2023) Vol. 8, Iss. 12
Open Access | Times Cited: 81
Semaglutide reduces alcohol intake and relapse-like drinking in male and female rats
Cajsa Aranäs, Christian E. Edvardsson, Olesya T. Shevchouk, et al.
EBioMedicine (2023) Vol. 93, pp. 104642-104642
Open Access | Times Cited: 56
Obesity and the kidney: mechanistic links and therapeutic advances
Kevin Yau, Rachel Kuah, David Z.I. Cherney, et al.
Nature Reviews Endocrinology (2024) Vol. 20, Iss. 6, pp. 321-335
Closed Access | Times Cited: 31
Dissociable hindbrain GLP1R circuits for satiety and aversion
Kuei-Pin Huang, Alisha A Acosta, Misgana Y. Ghidewon, et al.
Nature (2024) Vol. 632, Iss. 8025, pp. 585-593
Closed Access | Times Cited: 30
Growth differentiation factor 15 (GDF-15) in endocrinology
Pedro Iglesias, Ramona A. Silvestre, Juan J. Díez
Endocrine (2023) Vol. 81, Iss. 3, pp. 419-431
Closed Access | Times Cited: 23
Changes in food preferences and ingestive behaviors after glucagon-like peptide-1 analog treatment: techniques and opportunities
Sahana Bettadapura, Katherine Dowling, Kelli Jablon, et al.
International Journal of Obesity (2024)
Open Access | Times Cited: 10
Activity-balanced GLP-1/GDF15 dual agonist reduces body weight and metabolic disorder in mice and non-human primates
Yuanyuan Zhang, Xinyu Zhao, Xiaona Dong, et al.
Cell Metabolism (2023) Vol. 35, Iss. 2, pp. 287-298.e4
Open Access | Times Cited: 20
Regulation of Fructose Metabolism in Nonalcoholic Fatty Liver Disease
Mareca Lodge, Rachel Dykes, Arion Kennedy
Biomolecules (2024) Vol. 14, Iss. 7, pp. 845-845
Open Access | Times Cited: 6
IUPHAR review – Glucagon-like peptide-1 (GLP-1) and substance use disorders: An emerging pharmacotherapeutic target
Nicolaus Bruns, Elizabeth H. Tressler, Leandro F. Vendruscolo, et al.
Pharmacological Research (2024) Vol. 207, pp. 107312-107312
Open Access | Times Cited: 6
Glucagon augments the secretion of FGF21 and GDF15 in MASLD by indirect mechanisms
Michael M. Richter, I Kemp, Sara Heebøll, et al.
Metabolism (2024) Vol. 156, pp. 155915-155915
Open Access | Times Cited: 5
Growth differentiation factor 15 (GDF15) levels are associated with malnutrition in acutely admitted older adults
Rikke Lundsgaard Nielsen, Olivia Bornæs, Esben Iversen, et al.
Clinical Nutrition (2024) Vol. 43, Iss. 8, pp. 1685-1693
Open Access | Times Cited: 5
Circulating total and intact GDF-15 levels are not altered in response to weight loss induced by liraglutide or lorcaserin treatment in humans with obesity
Laura Valenzuela‐Vallejo, Pavlina Chrysafi, Jenny C. Bello-Ramos, et al.
Metabolism (2022) Vol. 133, pp. 155237-155237
Closed Access | Times Cited: 20
Nausea-induced suppression of feeding is mediated by central amygdala Dlk1-expressing neurons
W. Ding, Helena Weltzien, Christian Peters, et al.
Cell Reports (2024) Vol. 43, Iss. 4, pp. 113990-113990
Open Access | Times Cited: 4
Weight-loss maintenance is accompanied by interconnected alterations in circulating FGF21-adiponectin-leptin and bioactive sphingolipids
Matteo Fiorenza, Antonio Checa, Rasmus M. Sandsdal, et al.
Cell Reports Medicine (2024) Vol. 5, Iss. 7, pp. 101629-101629
Open Access | Times Cited: 4
Superior metabolic improvement of polycystic ovary syndrome traits after GLP1-based multi-agonist therapy
Miguel A. Sánchez-Garrido, Víctor Serrano-López, Francisco Ruíz-Pino, et al.
Nature Communications (2024) Vol. 15, Iss. 1
Open Access | Times Cited: 4
A growth-differentiation factor 15 receptor agonist in randomized placebo-controlled trials in healthy or obese persons
William B. Smith, D. Le Nguyen, Timothy M. Clough, et al.
The Journal of Clinical Endocrinology & Metabolism (2024)
Open Access | Times Cited: 3
Chronic Semaglutide Treatment in Rats Leads to Daily Excessive Concentration-Dependent Sucrose Intake
Carolina R. Cawthon, Ginger D. Blonde, A. Valentina Nisi, et al.
Journal of the Endocrine Society (2023) Vol. 7, Iss. 7
Open Access | Times Cited: 7
GLP-1 receptor agonist semaglutide reduces appetite while increasing dopamine reward signaling
Karlijn L. Kooij, Derek IJsbrand Koster, E. Eeltink, et al.
Neuroscience Applied (2023) Vol. 3, pp. 103925-103925
Open Access | Times Cited: 7
Central mechanisms of emesis: A role for GDF15
Tito Borner, Allison M. Pataro, Bart C. De Jonghe
Neurogastroenterology & Motility (2024)
Open Access | Times Cited: 2
GDF15 is still a mystery hormone
Casper M. Sigvardsen, Michael M. Richter, Sarah Engelbeen, et al.
Trends in Endocrinology and Metabolism (2024)
Closed Access | Times Cited: 2
Poly-Agonist Pharmacotherapies for Metabolic Diseases: Hopes and New Challenges
C. Allard, Daniela Cota, Carmelo Quarta
Drugs (2023) Vol. 84, Iss. 2, pp. 127-148
Closed Access | Times Cited: 6
Total and H‐specific growth/differentiation factor 15 levels are unaffected by liraglutide or naltrexone/bupropion administration
Sofia Konstantinidou, Georgia Argyrakopoulou, Stamatia Simati, et al.
Diabetes Obesity and Metabolism (2024) Vol. 26, Iss. 8, pp. 3147-3154
Closed Access | Times Cited: 2
Creation of a Peptide Antagonist of the GFRAL–RET Receptor Complex for the Treatment of GDF15-Induced Malaise
Tito Borner, Ian C. Tinsley, Brandon T. Milliken, et al.
Journal of Medicinal Chemistry (2023) Vol. 66, Iss. 16, pp. 11237-11249
Open Access | Times Cited: 5
Regulation of Energy and Glucose Homeostasis by the Nucleus of the Solitary Tract and the Area Postrema
Kyla Bruce, Ameth N. Garrido, Song‐Yang Zhang, et al.
Endocrinology and Metabolism (2024) Vol. 39, Iss. 4, pp. 559-568
Open Access | Times Cited: 1
Liraglutide-induced effects on energy intake and glycemic profile are independent of total and intact GDF-15 levels in subjects with obesity and diabetes
Laura Valenzuela‐Vallejo, Pavlina Chrysafi, Christos S. Mantzoros
Diabetes & Metabolism (2022) Vol. 48, Iss. 5, pp. 101369-101369
Closed Access | Times Cited: 6
Page 1 - Next Page

Scroll to top